CytivaTM RNA delivery LNP kit

Cytiva^™ RNA delivery LNP kit

Pre-optimized ionizable lipid mix for RNA-LNP delivery to accelerate lead candidate selection

The RNA delivery LNP kit for the NanoAssemblr™ Ignite™ system and Ignite+™ system offers a ready–to–use ionizable lipid composition to fast-track payload and lipid nanoparticle (LNP) screening for RNA drug delivery validation, progressing lead candidates quickly through preclinical studies accelerating clinical evaluation of novel nanomedicines.

This off-the-shelf RNA delivery kit lowers the barrier to entry for LNP formulations, particularly for vaccine developers as this kit removes complexity from the formulation development process. It comes with comprehensive protocols and proof-of-concept data, supporting both in vitro and in vivo delivery of mRNA and self-amplifying RNA (saRNA) for infectious disease vaccine research.

This streamlined approach can significantly shorten development timelines.

Accelerate your LNP screening and drug delivery milestones

Easy to use

Lower the barrier to entry for LNP formulation and drug development

Confidently produce LNPs using prepared reagents and protocols, designed to validate RNA drug delivery quickly and easily without prior LNP formulation experience.

High-quality and stable LNPs

Obtain consistent LNP physicochemical characteristics and potency

Achieve robust LNP characterization, ensuring homogenous and reproducible nanoparticles with demonstrated stability, protection against RNA degradation, and long shelf-life.

Scalable LNP technologies

De-risk drug development with lipids and mixing technologies that scale

Advance with consistent LNP formulation on NanoAssemblr^TM platforms using ionizable lipids that can validate RNA drug delivery and be licensed for clinical evaluation

Streamline payload screening

and LNP optimization

Accelerate lead candidate selection

Benefit from ready-made ionizable lipid mix for RNA-LNP delivery, leveraging our demonstrated experience to decisively screen and fast-track lead candidates through preclinical stages.

Proof of concept data for infectious

disease vaccines

Gain efficiency from optimized workflow and protocols for infectious disease vaccine development

Access LNP potency data demonstrating in vitro protein expression and in vivo immunogenicity for

mRNA vaccine applications, accelerating

vaccine development.

Fill out the form to request the RNA-LNP vaccine case study, to learn how pre-optimized formulations can accelerate development, and to discuss your own custom project with our specialists!